SHANGHAI FUDAN-ZHANGJIAN BIO-PHARM financial statements, including revenue, expenses, profit, and loss
The total revenue of 1349 for the last quarter is 152.72 M HKD, and it's 22.92% lower compared to the previous quarter. The net income of Q4 23 is 20.25 M HKD.